OS Therapies Announces Q2 2026 Results and Regulatory Update

OSTX OS Therapies Inc

$1.49 -6.88%

View chart & analysis →

MEDS -8.36%

1. 1OS Therapies (OSTX) reported Q2 results for the period ended June 30, 2026, and provided an update on OST-HER2 regulatory progress
2. 2Net operating loss of $8.576 million, or $0.20 per share; VAT refunds receivable exceed $3 million, with at least $4.2 million in Q3 R&D tax credits expected to be recognized
3. 3Plans to pursue FDA accelerated approval BLA and UK/EU CMAA submissions in H2 for OST-HER2 in completely resected pulmonary metastatic osteosarcoma

Source Newsfile Corp. +1 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →